George Bebawy

George Bebawy

Auto-generated profile, based on publicly available information

George Bebawy

Pharmaceutics Department, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2021 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
GBGeorge Bebawy
George Bebawy
MSMagda Sokar
Magda Sokar
OAOssama Y. Abdallaha
Ossama Y. Abdallaha
Objective Risperidone is a potent psychotropic agent has been approved for symptomatic treatment of irritability in children and adolescents with autism spectrum disorders. However, its bitter taste and dose adjustment of liquid dosage forms are a main hurdle for patient acceptance. Significance Thus, this recent study investigate the formulation of taste masked risperidone orally disintegration minitablets (ODMT) as a way of enhancing patient acceptance. Methods Taste masked risperidone hydrogenated castor oil or Cetyl alcohol based granules were prepared using a simple melt granulation technique in different drug to lipid ratios; drug release, bitterness score of the prepared granular formulations were evaluated. DSC was also performed to detect the possible drug lipid interaction. The selected lipid-based granules were further compressed into ODMT formulations. Bitterness score was assessed by gustatory sensation test and results were compared to marketed liquid formulations of risperidone. Results All the prepared ODMT formulations showed high content uniformity, with minimum dose fluctuation compared to marketed oral liquid preparations. Conclusion In conclusion, risperidone lipid-based granules could be formulated in different ratios by simple techniques and commonly used excipients into taste masked risperidone ODMT with accurate and flexible doses suitable for pediatric use with high taste preference and acceptability.

14 April 2025 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
GBGeorge Bebawy
George Bebawy
PCPamela Collier
Pamela Collier
Phil WilliamsPhil Williams
Phil Williams
Jonathan C. BurleyJonathan C. Burley
Jonathan C. Burley
DNDavid Needham
David Needham
Many cancers overexpress low-density lipoprotein receptors (LDLR), facilitating cholesterol metabolism for tumour growth. Targeting LDLR offers a promising strategy for selective drug delivery. Orlistat, a fatty acid synthase (FAS) inhibitor, has shown anti-cancer potential, particularly in tumours with high FAS expression. This study introduces an LDLR-Orlistat Targeted Nanoparticles (LDLR-OTNs) to enhance cancer cell uptake via LDLR-mediated endocytosis. The objectives include synthesizing lipid-based orlistat nanoparticles, functionalizing them with an 11-mer LDLR-binding peptide, assessing uptake and cytotoxicity in three LDLR- and FAS-expressing breast cancer cell lines (BT-474, MDA MB 453, MCF-7), and comparing uptake kinetics with non-targeted nanoparticles. Orlistat nanoparticles (ONs) were synthesised via rapid solvent exchange, producing uncoated ONs, POPC-coated ONs (POPC-ONs), and LDLR-targeted ONs (LDLR-OTNs). Targeting was achieved by conjugating an 11-mer binding peptide (RLTRKRGLKLA) to DSPE-PEG5000 maleimide via click chemistry, confirmed by Ellman's test. Nanoparticles were characterised using DLS and TEM. Cellular uptake over 24 hours was assessed using fluorescence-labelled POPC-ONs and LDLR-OTNs, and uptake kinetics were analysed. Suramin-blocking studies were used to confirm LDLR-mediated uptake. A 48-hour cytotoxicity assay quantified IC50 values in the aforementioned cell lines. TEM data showed that LDLR-OTNs (33 nm) were smaller than untargeted POPC-ONs (58 nm) and uncoated ONs (67 nm). Ellman's test confirmed > 99.2% peptide conjugation. Cellular uptake of LDLR-OTNs was rapid, with significant fluorescence by 1 hour and a kinetic plateau at 24-48 hours, with data fitting to a modified exponential model, while that of untargeted POPC-ONs had lower initial uptake, following a logistic model. Suramin blocking reduced LDLR-OTN uptake, confirming receptor-mediated entry. Cytotoxicity assays yielded IC50 values of 23.8 µM (BT-474), 25.8 µM (MDA MB 453), and 8.2 µM (MCF-7), with maximal inhibition at 48 h. LDLR-OTNs demonstrated receptor-mediated uptake and potent cytotoxicity in LDLR- and FAS- overexpressing breast cancer cells. These findings support LDLR-targeted nanoparticles as a promising approach for delivering FAS inhibitors to LDLR-rich tumours, meriting further investigation in targeted cancer therapy development.

21 April 2026 in Pharmaceutical Research
Verified
Journal Article
Open access
PDF file
JYJulie R. Youssef
Julie R. Youssef
EEEsraa M. Elgammal
Esraa M. Elgammal
DMDina M. Mahdy
Dina M. Mahdy
NGNoha F. Ghazi
Noha F. Ghazi
GBGeorge Bebawy
George Bebawy
Breast cancer remains the most prevalent malignancy among women worldwide and a major cause of cancer-related mortality. Despite remarkable progress in molecularly targeted and immune-based therapies, therapeutic resistance, dose-limiting systemic toxicity, and inefficient drug delivery continue to hinder clinical outcomes, particularly in aggressive subtypes such as triple-negative breast cancer. Exosomes, naturally secreted nanosized vesicles, have emerged as a transformative platform owing to their biocompatibility, intrinsic targeting capability, and ability to transport diverse therapeutic cargos across biological barriers. Recent advances in exosome biology, engineering, and isolation technologies have reignited interest in their clinical exploitation as drug delivery systems. However, translation into clinical oncology remains in its early stages. This review provides a comprehensive overview of exosome-based drug delivery systems specifically within the context of breast cancer therapy, critically evaluating their sources, isolation techniques, cargo loading strategies, targeting mechanisms, and formulation considerations. It also examines preclinical findings demonstrating enhanced therapeutic efficacy and reduced off-target toxicity, alongside the limited yet growing number of clinical trials investigating exosome therapeutics in solid tumours. Importantly, the review identifies major gaps, including lack of standardized manufacturing protocols, incomplete pharmacokinetic understanding, and unresolved safety concerns, that currently impede clinical translation. By bridging molecular insights with translational perspectives, this work underscores the untapped potential of exosomes as next-generation drug carriers in breast cancer. It highlights the urgent need for harmonized methodologies, scalable production systems, and regulatory frameworks to enable their safe and effective integration into future cancer therapeutics. Graphical Abstract The alternative text for this image may have been generated using AI.

29 December 2025 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
GBGeorge Bebawy
George Bebawy
AHAsmaa Hegazy
Asmaa Hegazy
AHAhmed H. Hassanin
Ahmed H. Hassanin
NSNader Shehata
Nader Shehata
ARalyaa ramadan
alyaa ramadan
HBHebatallah S. Barakat
Hebatallah S. Barakat

6 November 2025 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
GBGeorge Bebawy
George Bebawy
JSJulie Sanderson
Julie Sanderson
SQSheng Qi
Sheng Qi
Additive manufacturing approaches enable the rapid production of drug-eluting contact lenses (DECLs) directly from commercially available lenses. Nanoelectrospraying (nES) is a promising additive technique, capable of applying drug coatings within seconds per lens. However, DECLs made by nES share similar challenges to DECLs made by other methods, including minimising drug loss into the packaging solution and achieving controlled drug release. In this study, bimatoprost, a drug widely used in glaucoma therapy, was selected as a model compound to develop a double-layered, pH-responsive DECL system incorporating drug-loaded NPs. The bimatoprost-loaded NPs were prepared using flash nanoprecipitation with zein and hyaluronic acid (HA). They were characterised for size, zeta potential, and entrapment efficiency. A double-layer coating was applied using nES, with the base layer comprising NPs in polyvinyl alcohol (PVA) and the top layer using Eudragit L100 for pH-responsive drug release. DECLs were evaluated for coating uniformity, optical transmittance, and storage stability. Comparative in vitro drug release studies were performed under static conditions and with a custom 3D-printed tear flow simulating device (TFS) to simulate physiological tear dynamics. Bimatoprost-loaded NPs exhibited a reasonable colloidal stability and entrapment efficiency. Drug release from soaked lenses (as the control sample) or nES single-layer-coated lenses was rapid, highlighting the need for advanced coating approaches. Storage stability studies confirmed drug retention of the DECLs with the double-layer coating, with minimal loss over storage at pH 5.5. Under physiological pH (pH 7.4), sustained drug release was achieved, demonstrating a 34% reduction in burst release and a significant increase in sustained release to single-layer coatings and soaked lenses. In conclusion, the double-layered, nanoparticle-loaded DECLs with a pH-responsive coating effectively demonstrated sustained drug release at physiological pH, with significantly reduced drug loss during storage in packaging solution. This scalable platform has the potential for DECL manufacturing which provides an alternative ocular drug delivery solution for chronic conditions like glaucoma.

23 October 2025 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
GBGeorge Bebawy
George Bebawy
AAAsmaa A. Ashour
Asmaa A. Ashour
RERiham El-Moslemany
Riham El-Moslemany
SESalma El-Habashy
Salma El-Habashy
BKBassant Kamal
Bassant Kamal
LHLamia A Heikal
Lamia A Heikal